BREAKING: Capricor Therapeutics Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Learn More

Block & Leviton is investigating Capricor Therapeutics for potential securities law violations related to misrepresentations about its deramiocel cell therapy regulatory pathway. The FDA concluded the therapy lacked substantial evidence of effectiveness, contradicting the company's prior statements about its Biologics License Application being on track. Capricor shares fell over 60% following the FDA's negative assessment.